InsiderClue
← All stocks

GENELUX Corp

GNLX Net selling
CIK 0001231457 #4219 in the set updated 17 Sep 2026
Bought (120 mo)
$1.25K
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$16.76M
$113.26K on a plan · $1.03M straight out of an exercise
Sold at will
$15.62M
125 of 139 sales
Net
−$16.76M
−$15.61M against sales at will

By person

17 insiders · 149 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Szalay Aladar
10% owner
—
$11.81M (59)
−$11.81M
599,821
1.33%
$1.65M
−23.7%
Yu Yong
Chief Scientific Officer
— (1)
$3.27M (26)
−$3.27M
258,688
0.5717%
$712.19K
+65.5%
Thomas John
Director
— (1)
$454.50K (10)
−$454.50K
501,193
1.11%
$1.38M
—
Zindrick Thomas
President and CEO
— (1)
$447.12K (9)
−$447.12K
1,426,427
3.15%
$3.93M
+21,257%
Ryder Sean
General Counsel
— (1)
$332.50K (4) scheduled
−$332.50K
47,621
0.1053%
$131.11K
+2,161%
Cappello Joseph
Chief Technical Officer
—
$154.44K (10)
−$154.44K
318,480
0.7039%
$876.81K
—
Tyree James L
Director
— (1)
$131.98K (4)
−$131.98K
96,483
0.2132%
$265.63K
+5,477%
Smither John W
Director
— (1)
$53.60K (2)
−$53.60K
91,403
0.2020%
$251.64K
+10,056%
Smalling Ralph
Head of Regulatory
— (1)
$43.28K (11)
−$43.28K
67,611
0.1494%
$186.14K
+1,067%
Samuelson Doug
Vice President, Finance
—
$30.78K (1)
−$30.78K
2,303
0.0051%
$6.34K
—
Jewett Caroline
Head of Quality
—
$22.74K (2)
−$22.74K
16,174
0.0357%
$44.53K
—
Zak Lourie S.
Chief Financial Officer
— (1)
$4.92K (1)
−$4.92K
82,452
0.1822%
$227.00K
+1,152%
Zhang Qian
Associate VP, Research
$1.25K (1)
—
+$1.25K
139,533
0.3084%
$384.15K
+4.7%
Mirabelli Mary
Director
— (1)
—
$0.00
102,693
0.2270%
$282.72K
—
Pulisic Matthew
Chief Financial Officer
—
—
—
278,906
0.6164%
$767.86K
—
Groen Eric
General Counsel
—
—
—
233,957
0.5171%
$644.11K
—
Woodward Gabe
Director
—
—
—
6,984
0.0154%
$19.23K
—

Individual transactions

10
Insider
Date
Role
Action
Shares
Price
Amount
Zak Lourie S.
29 May 2024
Chief Financial Officer
Buy
31,250
—
no price
Ryder Sean
29 May 2024
General Counsel
Buy
10,000
—
no price
Smalling Ralph
29 May 2024
Head of Regulatory
Buy
1,250
—
no price
Zindrick Thomas
29 May 2024
President and CEO
Buy indirect
200,000
—
no price
Yu Yong
29 May 2024
VP, Clinical Trial Operations
Buy
2,500
—
no price
Mirabelli Mary
29 May 2024
Director
Buy
8,000
—
no price
Thomas John
29 May 2024
Director
Buy
2,500
—
no price
Smither John W
29 May 2024
Director
Buy
6,250
—
no price
Tyree James L
29 May 2024
Director
Buy
6,250
—
no price
Zhang Qian
26 Jan 2023
Associate VP, Research
Buy indirect
200
$6.25
$1.25K
Show all 149 transactions →

What was left out

Form 4 filings counted 163
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 4
Sales straight out of an exercise 10
Sales at will 125
Transactions with no price 9
Shares from compensation/vesting 4,605,497
History held since 30 Jan 2023